Compass Therapeutics Financial Results
Compass Therapeutics reported Q3 2026 financial results, ending the period with $163 million in cash and marketable securities, which is expected to fund operations into 2028. The company is currently preparing for a BLA submission for tovecimig in biliary tract cancer (BTC) and plans to engage the FDA regarding the necessity of additional survival studies.
- Term
- Q3 2026
“The third quarter was a period of sustained execution across our pipeline. We continue to prepare the BLA submission for tovecimig and are working to engage the FDA to bring this important therapy to patients with BTC as quickly as possible. The full COMPANION-002 results, now published in the Journal of Clinical Oncology and presented at ESMO, highlight the strength of the supportive data for tovecimig.”
Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors
“We are confident in the role tovecimig can play in the biliary tract cancer treatment landscape. We are committed to bringing tovecimig to patients as quickly as possible and the totality of the tovecimig data reinforces the urgency of our engagement with the FDA to define the most efficient path to a BLA submission.”
Thomas Schuetz, MD, PhD, Chief Executive Officer and Vice Chairman of the Board of Directors